Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03512171 · ClinicalTrials.gov registry record · Phase 1
Decision Making Study in Young and Middle-Aged Adults: Part II
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT03512171 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 65 participants.
The verdict
NCT03512171, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
Financial decisions are made during pre-retirement age that can influence financial well-being for the rest of an individual's life. This proposal aims to construct a more comprehensive model of the specific psychological and neural mechanisms that support financial decisions in young adulthood and late middle age. In Part 1 of this study (covered in Institutional Review Board (IRB) # 141812), middle-age and young adults complete basic cognitive, motivational, and decision making tasks and are studied with functional magnetic resonance imaging (fMRI) to determine the relation between neural circuit activation and individual and age-related differences in decision making. In part II of the study, aspects of dopamine functioning are studied using positron emission tomography (PET) scanning to determine whether individual differences in dopamine functions are related to the decision-making and fMRI measures collected in Part 1 of the study. Dopamine measures include baseline D2 receptor availability, amphetamine induced dopamine release and dopamine transporter (DAT) levels, which provides a more comprehensive evaluation of dopamine functions than in prior studies linking individual differences in dopamine to behavioral, cognitive or decision-making traits.
Interventions
- DRUG Placebo
- DRUG Dextroamphetamine
- DIAGNOSTIC_TEST [18F]Fallypride
- DIAGNOSTIC_TEST [18F]-FE-PE2I
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2016-03-31 |
| Est. Completion | 2018-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03512171
The ClinicalTrials.gov registry entry for NCT03512171 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03512171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03512171 about?
NCT03512171 is a clinical study titled "Decision Making Study in Young and Middle-Aged Adults: Part II". Financial decisions are made during pre-retirement age that can influence financial well-being for the rest of an individual's life. This proposal aims to construct a more comprehensive model of the specific psychological and neural mechanisms that support financial decisions in young adulthood and ...
What is the current status of trial NCT03512171?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2016-03-31. Estimated completion is 2018-05-15.
What interventions are being tested in trial NCT03512171?
The interventions under investigation include: Placebo (DRUG), Dextroamphetamine (DRUG), [18F]Fallypride (DIAGNOSTIC_TEST), [18F]-FE-PE2I (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03512171?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.